Nicolet Bankshares’s Pfizer PFE Stock Holding History

Nicolet Bankshares’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.62M	Sell	109,634 -3,649	-3%	-$95.5K	0.08%	175
2026 Q1	$3.2M	Buy	113,283 +66,879	+144%	+$1.78M	0.12%	138
2025 Q4	$1.16M	Buy	46,404 +1,012	+2%	+$25.5K	0.19%	86
2025 Q3	$1.16M	Buy	45,392 +10,626	+31%	+$262K	0.19%	88
2025 Q2	$843K	Buy	34,766 +2,704	+8%	+$63.1K	0.15%	106
2025 Q1	$812K	Sell	32,062 -1,269	-4%	-$33.2K	0.16%	99
2024 Q4	$884K	Sell	33,331 -10,774	-24%	-$292K	0.21%	94
2024 Q3	$1.28M	Buy	44,105 +4,849	+12%	+$141K	0.31%	75
2024 Q2	$1.1M	Sell	39,256 -2,123	-5%	-$58.4K	0.27%	79
2024 Q1	$1.15M	Buy	41,379 +1,533	+4%	+$42.5K	0.28%	85
2023 Q4	$1.15M	Buy	39,846 +318	+0.8%	+$9.61K	0.31%	76
2023 Q3	$1.31M	Sell	39,528 -11,229	-22%	-$397K	0.4%	56
2023 Q2	$1.47M	Buy	50,757 +7,426	+17%	+$289K	0.42%	55
2023 Q1	$1.36M	Buy	43,331 +1,327	+3%	+$57.3K	0.44%	50
2022 Q4	$1.64M	Sell	42,004 -59	-0.1%	-$2.83K	0.57%	40
2022 Q3	$1.84M	Buy	42,063 +434	+1%	+$21.1K	0.53%	35
2022 Q2	$2.18M	Buy	41,629 +485	+1%	+$24.7K	0.57%	30
2022 Q1	$2.13M	Buy	41,144 +3,113	+8%	+$162K	0.46%	39
2021 Q4	$2.25M	Buy	38,031 +938	+3%	+$46.5K	0.5%	34
2021 Q3	$1.59M	Buy	37,093 +229	+0.6%	+$10.1K	0.41%	45
2021 Q2	$1.44M	Buy	36,864 +651	+2%	+$25.3K	0.38%	49
2021 Q1	$1.31M	Sell	36,213 -79	-0.2%	-$2.81K	0.36%	49
2020 Q4	$1.34M	Sell	36,292 -1,615	-4%	-$59.2K	0.41%	45
2020 Q3	$1.32M	Buy	37,907 +647	+2%	+$22.7K	0.46%	41
2020 Q2	$1.16M	Buy	37,260 +90	+0.2%	+$3.06K	0.44%	43
2020 Q1	$1.15M	Sell	37,170 -2,186	-6%	-$74.5K	0.52%	35
2019 Q4	$1.46M	Sell	39,356 -77	-0.2%	-$2.74K	0.54%	40
2019 Q3	$1.34M	Sell	39,433 -1,586	-4%	-$57.7K	0.54%	40
2019 Q2	$1.69M	Sell	41,019 -25	-0.1%	-$993	0.7%	25
2019 Q1	$1.65M	Buy	41,044 +4,757	+13%	+$191K	0.68%	25
2018 Q4	$1.5M	Buy	36,287 +105	+0.3%	+$4.36K	0.72%	25
2018 Q3	$1.51M	Buy	36,182 +224	+0.6%	+$8.62K	0.61%	28
2018 Q2	$1.24M	Sell	35,958 -2,159	-6%	-$73.8K	0.52%	35
2018 Q1	$1.28M	Sell	38,117 -1,634	-4%	-$56.2K	0.55%	33
2017 Q4	$1.37M	Buy	39,751 +9,245	+30%	+$315K	0.59%	32
2017 Q3	$1.03M	Sell	30,506 -1,010	-3%	-$32.5K	0.46%	42
2017 Q2	$1M	Sell	31,516 -1,981	-6%	-$62.5K	0.47%	43
2017 Q1	$1.09M	Sell	33,497 -3,526	-10%	-$111K	0.57%	36
2016 Q4	$1.14M	Buy	37,023 +5	+0%	+$153	0.62%	31
2016 Q3	$1.19M	Buy	37,018 +3,188	+9%	+$107K	0.69%	29
2016 Q2	$1.13M	Buy	33,830 +5,632	+20%	+$180K	0.74%	25
2016 Q1	$793K	Hold	28,198	–	–	0.56%	33
2015 Q4	$816K	Buy	+28,198	New	+$887K	0.81%	28

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nicolet Bankshares's PFE Position: Q2 2026 in Review

Nicolet Bankshares reduced its Pfizer (PFE) stake by 3.2% in Q2 2026, selling an estimated $95.5K and leaving 109,634 shares worth $2.62M. The position accounts for 0.08% of the portfolio, ranked #175.

Nicolet Bankshares first reported a position in PFE in Q4 2015 and has held it in 43 quarters since. The position peaked at $3.2M in Q1 2026. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Nicolet Bankshares held 109,634 shares of Pfizer worth $2.62M as of Q2 2026.
Nicolet Bankshares sold 3,649 Pfizer shares in Q2 2026, an estimated $95.5K.
Pfizer made up 0.08% of Nicolet Bankshares's portfolio in Q2 2026, its #175 holding.
Nicolet Bankshares first reported a position in Pfizer in Q4 2015 and has held it in 43 quarters since.
Nicolet Bankshares's Pfizer position peaked at $3.2M in Q1 2026.
2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Nicolet Bankshares's 13F filing for Q2 2026, filed 11 Aug 2026.